MyoKardia
Global biopharmaceutical company focused on discovery, development and delivery of medicines across oncology, immunology, hematology and cardiovascular diseases. Maintains end-to-end R&D and development capabilities—selecting targets based on human biology, applying diverse therapeutic modalities, and advancing candidates through translational medicine and clinical development. Provides global clinical trial resources, pharmacovigilance, medical information, patient support programs and manufacturing operations.
Industries
Nr. of Employees
large (251-1000)
MyoKardia
Bristol Myers Squibb Corporate Headquarters, Route 206 & Province Line Road, Princeton, New Jersey 08543
Patents
Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
US-12344607-B2
View DetailsSubstituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
US-11034693-B2
View Details
Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
US-12344607-B2
View DetailsSubstituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseases
US-11034693-B2
View DetailsExpertise Areas
- Clinical trial management
- Translational medicine and target validation
- Therapeutic modality development (cell therapy, biologics, small molecules, ADCs)
- Regulatory compliance and safety reporting
Key Technologies
- Cell therapy
- Targeted protein degradation
- Radiopharmaceuticals
- Antibody-drug conjugates
News & Updates
Article describing ongoing lung cancer research, biological insights and commitment to improving patient outcomes.
Press release reporting third quarter 2025 financial results.
Article describing ongoing lung cancer research, biological insights and commitment to improving patient outcomes.
Press release reporting third quarter 2025 financial results.